Detalles de la búsqueda
1.
A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
Eur J Neurol
; 29(9): 2744-2753, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35590453
2.
Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry.
Pain Med
; 23(4): 745-760, 2022 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480564
3.
Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
Neurodegener Dis
; 21(3-4): 55-62, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34731865
4.
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Int J Neurosci
; 130(12): 1199-1205, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32065006
5.
A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols.
Ther Adv Neurol Disord
; 16: 17562864231195513, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37745913
6.
Systematic reviews of randomized controlled trials of cannabinoid products in chronic pain conditions and for symptoms associated with multiple sclerosis: what do they tell us?
Expert Rev Clin Pharmacol
; 15(4): 415-431, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35679523
7.
A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
Expert Rev Neurother
; 22(6): 499-511, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35582858
8.
Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry.
J Pain Res
; 15: 267-286, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35140513
9.
Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
Expert Rev Neurother
; 21(5): 547-558, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33749480
10.
Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials.
Expert Rev Neurother
; 21(7): 755-778, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34092180
11.
Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses.
Eur J Health Econ
; 22(5): 711-721, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33880663
12.
Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
Expert Rev Med Devices
; 16(9): 835-840, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31393179
Resultados
1 -
12
de 12
1
Próxima >
>>